- Trials with a EudraCT protocol (81)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
81 result(s) found for: HER2 + Gastric Cancer AND Cancer.
Displaying page 1 of 5.
| EudraCT Number: 2019-004357-86 | Sponsor Protocol Number: GOIRC-05-2019 | Start Date*: 2020-07-17 | |||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
| Full Title: A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (G... | |||||||||||||
| Medical condition: HER2 positive advanced gastric or gastro-esophageal junction cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022699-30 | Sponsor Protocol Number: B-DOCT | Start Date*: 2011-01-19 | |||||||||||||||||||||
| Sponsor Name:Nederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis | |||||||||||||||||||||||
| Full Title: Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Me... | |||||||||||||||||||||||
| Medical condition: Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-004395-28 | Sponsor Protocol Number: MANTRA | Start Date*: 2014-12-24 | |||||||||||
| Sponsor Name:Azienda Ospedaliero-Universitaria di Parma | |||||||||||||
| Full Title: Phase II randomized study of maintenance regorafenib vs placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metas... | |||||||||||||
| Medical condition: HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011580-36 | Sponsor Protocol Number: 40071 | Start Date*: 2011-04-26 | |||||||||||
| Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer | |||||||||||||
| Full Title: Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surge... | |||||||||||||
| Medical condition: adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002570-23 | Sponsor Protocol Number: CAUY922A2205 | Start Date*: 2011-12-22 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-... | ||||||||||||||||||
| Medical condition: Patients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Prematurely Ended) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-000624-10 | Sponsor Protocol Number: AIO-STO-0217 | Start Date*: 2018-02-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTE... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: inoperable, advanced or metastatic untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-003031-38 | Sponsor Protocol Number: GOIRC-05-2016 | Start Date*: 2017-04-04 | |||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
| Full Title: Phase II randomized study of maintenance Regorafenib vs Placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metas... | |||||||||||||
| Medical condition: No progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-002331-25 | Sponsor Protocol Number: BP27836 | Start Date*: 2011-12-07 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | |||||||||||||
| Medical condition: HER2-positive adenocarcinoma of the stomach or gastroesophageal junction | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) BE (Completed) CZ (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003493-13 | Sponsor Protocol Number: BGB-290-303 | Start Date*: 2018-05-24 | |||||||||||
| Sponsor Name:BeiGene, Ltd. | |||||||||||||
| Full Title: A Phase 2, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based... | |||||||||||||
| Medical condition: Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) PL (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004699-21 | Sponsor Protocol Number: CP-MGAH22-06 | Start Date*: 2020-10-12 | |||||||||||||||||||||
| Sponsor Name:MacroGenics, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positiv... | |||||||||||||||||||||||
| Medical condition: Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2012-003798-25 | Sponsor Protocol Number: MM-111-13-02-04 | Start Date*: 2013-06-12 | |||||||||||||||||||||
| Sponsor Name:Merrimack Pharmaceuticals Inc. | |||||||||||||||||||||||
| Full Title: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, G... | |||||||||||||||||||||||
| Medical condition: HER2 distal esophageal, Gastroesophageal (GE) junction or gastric carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-001526-19 | Sponsor Protocol Number: BO27798 | Start Date*: 2011-12-28 | ||||||||||||||||
| Sponsor Name:F.Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients wi... | ||||||||||||||||||
| Medical condition: Metastatic HER2-positive adenocarcinoma of the stomach or gastro-esophageal junction. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-001402-23 | Sponsor Protocol Number: YO28322 | Start Date*: 2012-09-07 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | ||||||||||||||||||
| Full Title: A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPL... | ||||||||||||||||||
| Medical condition: GASTROESOPHAGEAL CANCER | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Temporarily Halted) IT (Completed) BE (Completed) GB (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-001605-14 | Sponsor Protocol Number: CCR4309 | Start Date*: 2015-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:The Royal Marsden NHS Foundation Trust | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced Gastric and Gastro-oesophageal cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-005646-15 | Sponsor Protocol Number: 21-BI-1607-01 | Start Date*: 2022-07-06 | ||||||||||||||||||||||||||
| Sponsor Name:BioInvent International AB | ||||||||||||||||||||||||||||
| Full Title: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors - CONT... | ||||||||||||||||||||||||||||
| Medical condition: HER2-positive locally Advanced unresectable or metastatic solid tumors in Phase 1 HER2+ breast cancer and subjects with HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma in Pha... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-019602-16 | Sponsor Protocol Number: | Start Date*: 2011-01-10 | ||||||||||||||||
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||||||||||||||||||
| Full Title: A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers | ||||||||||||||||||
| Medical condition: Oesophagogastric adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-009894-88 | Sponsor Protocol Number: NCT-2008-11-01-1015 | Start Date*: 2009-09-17 | ||||||||||||||||
| Sponsor Name:University Hospital of Heidelberg | ||||||||||||||||||
| Full Title: Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial | ||||||||||||||||||
| Medical condition: Gastric Cancer, cancer of the oesophago-gastric junction, esophageal cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-004415-39 | Sponsor Protocol Number: TO-TAS0728-101 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
| Sponsor Name:Taiho Oncology, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W... | |||||||||||||||||||||||||||||||||
| Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-001547-46 | Sponsor Protocol Number: MO28230 | Start Date*: 2012-08-22 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic ga... | ||||||||||||||||||
| Medical condition: Her2 postive metastatic breast cancer and Her2 positive locally advanced or metastatic gastric cancer. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Completed) FR (Completed) PT (Completed) SK (Completed) IT (Completed) DE (Completed) GR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-002512-49 | Sponsor Protocol Number: PRS-343-PCS_09_20 | Start Date*: 2022-06-13 |
| Sponsor Name:Pieris Pharmaceuticals, Inc. | ||
| Full Title: A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Aden... | ||
| Medical condition: HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
